Post-Market Studies: Even With New Powers, FDA Relies On Firms’ Judgments
Executive Summary
BOSTON - When it comes to setting deadlines for completing post-marketing safety studies, industry has the expertise, Office of New Drugs Deputy Director Sandra Kweder told the Drug Information Association meeting on June 24